AURORA, Colo., March 18 /PRNewswire/ -- Pharmatech Oncology has been selected by the Fitzsimons Redevelopment Authority to be a preferred vendor to the Colorado Science + Technology Park at Fitzsimons. The Technology Park is home to 25 pharmaceutical and biotechnology companies. The majority of the companies are in the research stage with a select number of companies expanding their research on commercial products. Pharmatech Oncology was chosen as a preferred vendor for its Contract Research, Site Management, and Data Management services within the realm of managing clinical research trials.
Forest City Science + Technology Group, in partnership with the Fitzsimons Redevelopment Authority, is developing the 184-acre Colorado Science + Technology Park at Fitzsimons. The synergy created by the research and development from the private bioscience companies, along with the clinical research endeavors of the
Rob Bohacs, Director of Business Development, Pharmatech Oncology, states that "Pharmatech Oncology is privileged to be a preferred vendor to the Colorado Science + Technology Park and to serve the companies within the life sciences cluster. It's exciting to witness the expansion of the Technology Park, as well as the significant medical research that is being conducted by its affiliated companies."
About Pharmatech Oncology:
Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the high
|SOURCE Pharmatech Oncology|
Copyright©2009 PR Newswire.
All rights reserved